GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 17.75
-0.05 (-0.28%)
May 29, 2026, 1:30 PM CST
GeneReach Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -105.32 | -110.28 | -118.73 | -166.27 | 221.34 | 376.62 |
Depreciation & Amortization | 66.63 | 69.44 | 73.73 | 68.03 | 64.28 | 59.24 |
Other Amortization | 1.66 | 1.66 | 1.01 | 0.86 | 0.89 | 0.77 |
Loss (Gain) From Sale of Assets | 14.11 | 13.5 | 28.17 | 1.39 | -1.7 | -0.41 |
Loss (Gain) From Sale of Investments | 8.74 | 9.05 | 2.57 | 2.5 | 3.7 | 3.81 |
Stock-Based Compensation | 3.23 | 2.02 | - | - | - | - |
Provision & Write-off of Bad Debts | -4.88 | -7.05 | -4.65 | 21.43 | -1.13 | 5.06 |
Other Operating Activities | -4.51 | -11.72 | -1.35 | -66.17 | -65.61 | 14.8 |
Change in Accounts Receivable | 12.41 | 10.74 | -16.97 | 12.04 | 138.08 | -31.15 |
Change in Inventory | 1.95 | 3.09 | 14.8 | 124.59 | 16.07 | -91.29 |
Change in Accounts Payable | 0.07 | -0.9 | 1.39 | -0.24 | -6.04 | -5.44 |
Change in Unearned Revenue | -3.81 | -0.67 | -0.55 | -2.84 | -11.49 | 13.17 |
Change in Other Net Operating Assets | -5.39 | 7.61 | -2.63 | -33.99 | -0.73 | 3.82 |
Operating Cash Flow | -15.11 | -13.52 | -23.22 | -38.67 | 357.63 | 348.99 |
Operating Cash Flow Growth | - | - | - | - | 2.48% | 105.51% |
Capital Expenditures | -6.81 | -6.36 | -7.12 | -23.53 | -49.87 | -19.56 |
Sale of Property, Plant & Equipment | 0.46 | 0.83 | 0.17 | - | 3.93 | 1.97 |
Sale (Purchase) of Intangibles | -4.08 | -6.01 | -1.34 | -3.82 | -0.59 | -1.36 |
Investment in Securities | 91.4 | 138.59 | -62.75 | -221.54 | - | 3.85 |
Other Investing Activities | 0.27 | -0.06 | 0.84 | -1.02 | -1.48 | -26.61 |
Investing Cash Flow | 82.06 | 127 | -70.21 | -249.91 | -48.01 | -41.7 |
Short-Term Debt Issued | - | 259 | 137 | 55 | - | - |
Long-Term Debt Issued | - | - | - | - | - | 198 |
Total Debt Issued | 259 | 259 | 137 | 55 | - | 198 |
Short-Term Debt Repaid | - | -294 | -70 | - | - | -2 |
Long-Term Debt Repaid | - | -11.19 | -47.58 | -201.94 | -19.35 | -8.82 |
Total Debt Repaid | -305.1 | -305.19 | -117.58 | -201.94 | -19.35 | -10.82 |
Net Debt Issued (Repaid) | -46.1 | -46.19 | 19.42 | -146.94 | -19.35 | 187.18 |
Repurchase of Common Stock | -17.31 | -17.31 | - | - | - | - |
Common Dividends Paid | - | - | - | - | -208.94 | -143.67 |
Other Financing Activities | - | -0.02 | -15.99 | -68.95 | - | -0.04 |
Financing Cash Flow | -63.41 | -63.52 | 3.43 | -215.89 | -228.28 | 43.48 |
Foreign Exchange Rate Adjustments | -2.31 | -5.17 | -16.5 | -27.37 | 3.84 | -1.01 |
Net Cash Flow | 1.24 | 44.8 | -106.5 | -531.84 | 85.18 | 349.75 |
Free Cash Flow | -21.92 | -19.87 | -30.35 | -62.21 | 307.76 | 329.43 |
Free Cash Flow Growth | - | - | - | - | -6.58% | 206.11% |
Free Cash Flow Margin | -9.43% | -8.54% | -14.70% | -27.59% | 41.03% | 32.55% |
Free Cash Flow Per Share | -0.38 | -0.35 | -0.53 | -1.08 | 5.19 | 5.62 |
Cash Interest Paid | 6.64 | 6.64 | 5.54 | 4.56 | 4.58 | 5.26 |
Cash Income Tax Paid | 6.28 | 6.28 | 5.4 | 14.03 | 117.39 | 78.3 |
Levered Free Cash Flow | 59.89 | -10.08 | -68.75 | 22.55 | 262.91 | 331.25 |
Unlevered Free Cash Flow | 63.65 | -6.02 | -65.04 | 26.15 | 267.04 | 335.16 |
Change in Working Capital | 5.22 | 19.87 | -3.96 | 99.56 | 135.88 | -110.9 |